|Over a week ago|
Swedish Orphan Biovitrum price target raised to SEK 160 from SEK 155 at Barclays » 11:1907/2307/23/21
Barclays analyst Rosie…
Barclays analyst Rosie Turner raised the firm's price target on Swedish Orphan Biovitrum to SEK 160 from SEK 155 and keeps an Equal Weight rating on the shares.
Swedish Orphan Biovitrum upgraded to Buy from Hold at Pareto » 05:0507/2207/22/21
Pareto analyst Peter…
Pareto analyst Peter Ostling upgraded Swedish Orphan Biovitrum to Buy from Hold with a SEK 195 price target.
Swedish Orphan Biovitrum upgraded to Buy from Hold at Deutsche Bank » 19:3307/2107/21/21
Deutsche Bank analyst…
Deutsche Bank analyst Emmanuel Papadakis upgraded Swedish Orphan Biovitrum to Buy from Hold with a SEK 200 price target. The analyst says the company's Q2 results confirmed stabilization and "some things to look forward to."
|Over a month ago|
Apellis, Swedish Orphan Biovitrum report results from Phase 3 Prince study » 07:0505/2505/25/21
Apellis Pharmaceuticals (APLS) and Swedish Orphan Biovitrum (BIOVF) reported positive top-line results from the Phase 3 PRINCE study evaluating the efficacy and safety of EMPAVELI in adults with paroxysmal nocturnal hemoglobinuria who are treatment naive, meaning they had not received a complement inhibitor within three months before entering the study. EMPAVELI demonstrated statistical superiority on the co-primary endpoints of hemoglobin stabilization and reduction in lactate dehydrogenase compared to standard of care, which did not include complement inhibitors, at Week 26. 86% of EMPAVELI-treated patients achieved hemoglobin stabilization compared to 0% of patients on standard of care. Hemoglobin stabilization was defined as an avoidance of a greater than1 g/dL decrease in hemoglobin levels in the absence of transfusions. Mean LDH in the EMPAVELI group decreased by 90% from a baseline of 2151 U/L to 211 U/L, which is within the normal range, compared to a 14% reduction on standard of care from a baseline of 1946 U/L to 1681 U/L.EMPAVELI also achieved statistical superiority on several secondary endpoints, including improvements in hemoglobin levels and transfusion avoidance, compared to standard of care, which did not include complement inhibitors. Mean hemoglobin levels in the EMPAVELI group increased from 9.4 g/dL to 12.1 g/dL compared to an increase from a baseline of 8.7 g/dL to 9.4 g/dL on standard of care. 91% of patients on EMPAVELI were transfusion free compared to 22% on standard of care. The safety profile of EMPAVELI was consistent with previous studies. At Week 26, 9% of patients in the EMPAVELI group experienced a serious adverse event compared to 17% on standard of care. One death was reported in each group, and neither were related to treatment. No cases of meningitis or thrombosis were reported in either group. The most common adverse events reported during the study in the EMPAVELI and standard of care groups, respectively, were injection site reaction, hypokalemia, and fever.
Swedish Orphan Biovitrum downgraded to Hold from Buy at DNB Markets » 05:1405/0505/05/21
DNB Markets analyst David…
DNB Markets analyst David Martinsson downgraded Swedish Orphan Biovitrum to Hold from Buy with a SEK 151 price target.
Swedish Orphan Biovitrum downgraded to Hold from Buy at SEB Equities » 05:1305/0505/05/21
SEB Equities analyst…
SEB Equities analyst Christopher Uhde downgraded Swedish Orphan Biovitrum to Hold from Buy.
|Over a quarter ago|
Swedish Orphan Biovitrum initiated with a Hold at Deutsche Bank » 06:0804/2004/20/21
Deutsche Bank analyst…
Deutsche Bank analyst Emmanuel Papadakis initiated coverage of Swedish Orphan Biovitrum with a Hold rating and SEK 130 price target. The analyst says the company's debt to EBITDA metrics "are still not obviously enticing."
Swedish Orphan Biovitrum participates in a conference call with Jefferies » 09:2303/0503/05/21
Healthcare Analyst Yang…
Healthcare Analyst Yang holds a conference call on March 5 at 10 am hosted by Jefferies.
Swedish Orphan Biovitrum downgraded to Equal Weight from Overweight at Barclays » 06:3802/2402/24/21
Barclays analyst Rosie…
Barclays analyst Rosie Turner downgraded Swedish Orphan Biovitrum to Equal Weight from Overweight with a price target of SEK 150, down from SEK 185. Increasing competitive pressure for the core haematology franchise, combined with COVID-related headwinds for parts of the immunology business signals the continuation of Biovitrum's earnings downgrade cycle, Turner tells investors in a research note.
Swedish Orphan Biovitrum downgraded to Hold from Buy at Danske Bank » 05:2002/1902/19/21
Danske Bank analyst…
Danske Bank analyst Daniel Albin downgraded Swedish Orphan Biovitrum to Hold from Buy with a SEK 164 price target.